Mirum Pharmaceuticals Inc MIRM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
-
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
Trading Information
- Previous Close Price
- $38.85
- Day Range
- $38.16–39.37
- 52-Week Range
- $23.14–45.23
- Bid/Ask
- $39.00 / $39.01
- Market Cap
- $1.86 Bil
- Volume/Avg
- 367,646 / 575,640
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.68
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 294
- Website
- https://www.mirumpharma.com
Comparables
Valuation
|
Metric
|
MIRM
|
RARE
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.07 | 11.60 | 1.74 |
Price/Sales | 6.68 | 9.15 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MIRM
RARE
PLRX
Financial Strength
|
Metric
|
MIRM
|
RARE
|
PLRX
|
|---|---|---|---|
Quick Ratio | 3.02 | 3.19 | 14.21 |
Current Ratio | 3.28 | 3.54 | 14.47 |
Interest Coverage | −7.57 | −8.24 | −106.49 |
Quick Ratio
MIRM
RARE
PLRX
Profitability
|
Metric
|
MIRM
|
RARE
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −6.21% | −31.64% | −27.65% |
Return on Equity (Normalized) | −17.90% | −218.50% | −31.11% |
Return on Invested Capital (Normalized) | −7.38% | −168.31% | −33.69% |
Return on Assets
MIRM
RARE
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Wdmkrxdsyj | Rmps | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yfgbdvllg | Kpzds | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gwfqghnhg | Rbdfcc | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kgynwvqyj | Mnhstj | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Qmynrgr | Cfkj | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Gqqklytj | Kdsk | $28.1 Bil | |||
| Moderna Inc
MRNA
| Bmgsqmryp | Yyjv | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Rqlmrbf | Fxzw | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qmcqwmm | Wsxgx | $13.4 Bil | |||
| Incyte Corp
INCY
| Bzgsfhz | Yxlzqc | $12.7 Bil |
United States